Literature DB >> 16425395

Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection.

Kazumoto Murata1, Kazushi Sugimoto, Katsuya Shiraki, Takeshi Nakano.   

Abstract

AIM: To determine the predictive factors for hepatocellular carcinoma (HCC) development in patients after spontaneous or therapeutic HBeAg seroconversion.
METHODS: In 48 patients who seroconverted to anti-HBe positive during follow-up, the background factors for HCC development were analyzed.
RESULTS: HCC was developed in six patients during follow-up (average follow-up after HBeAg seroconversion: 10.9+/-5.4 years). The incidence of HCC evaluated by Kaplan-Meier analysis was significantly higher in patients with abnormal aspartate aminotransferase (AST>40 IU/L) level, lower platelet counts (PLT< 10 x 10(4)/microL), lower albumin level (Alb<30 g/L), positive HBV-DNA or older age at seroconversion (>40 years). However, lower platelet count was the only predictive factor for HCC development shown by multivariate proportional-hazard analysis.
CONCLUSION: Active hepatitis or advanced hepatitis at HBeAg seroconversion or progressive hepatitis even after HBeAg seroconversion would be the risk factors for HCC development. These predictive factors should be taken into account in determining the frequency of biochemical study or imaging studies for HCC surveillance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16425395      PMCID: PMC4725028          DOI: 10.3748/wjg.v11.i43.6848

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  15 in total

Review 1.  NIH conference. Hepatocellular carcinoma.

Authors:  A M Di Bisceglie; V K Rustgi; J H Hoofnagle; G M Dusheiko; M T Lotze
Journal:  Ann Intern Med       Date:  1988-03       Impact factor: 25.391

2.  Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection.

Authors:  G Realdi; A Alberti; M Rugge; F Bortolotti; A M Rigoli; F Tremolada; A Ruol
Journal:  Gastroenterology       Date:  1980-08       Impact factor: 22.682

3.  Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis.

Authors:  G Fattovich; L Brollo; A Alberti; G Realdi; P Pontisso; G Giustina; A Ruol
Journal:  Liver       Date:  1990-06

Review 4.  Prevention of hepatitis B virus-related hepatocellular carcinoma.

Authors:  Anna S F Lok
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

5.  Natural history of chronic hepatitis B virus infection.

Authors:  M F Yuen; C L Lai
Journal:  J Gastroenterol Hepatol       Date:  2000-05       Impact factor: 4.029

6.  Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients.

Authors:  S Takano; O Yokosuka; F Imazeki; M Tagawa; M Omata
Journal:  Hepatology       Date:  1995-03       Impact factor: 17.425

7.  Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.

Authors:  Vito Di Marco; Alfredo Marzano; Pietro Lampertico; Pietro Andreone; Teresa Santantonio; Piero Luigi Almasio; Mario Rizzetto; Antonio Craxì
Journal:  Hepatology       Date:  2004-10       Impact factor: 17.425

8.  Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study.

Authors:  Y F Liaw; D Y Lin; T J Chen; C M Chu
Journal:  Liver       Date:  1989-08

9.  Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis.

Authors:  J H Hoofnagle; G M Dusheiko; L B Seeff; E A Jones; J G Waggoner; Z B Bales
Journal:  Ann Intern Med       Date:  1981-06       Impact factor: 25.391

10.  Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.

Authors:  C Niederau; T Heintges; S Lange; G Goldmann; C M Niederau; L Mohr; D Häussinger
Journal:  N Engl J Med       Date:  1996-05-30       Impact factor: 91.245

View more
  4 in total

Review 1.  Clinical impact of occult hepatitis B virus infection in immunosuppressed patients.

Authors:  Evangelista Sagnelli; Mariantonietta Pisaturo; Salvatore Martini; Pietro Filippini; Caterina Sagnelli; Nicola Coppola
Journal:  World J Hepatol       Date:  2014-06-27

2.  Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2.

Authors:  Noboru Shinkai; Yasuhito Tanaka; Kiyoaki Ito; Motokazu Mukaide; Izumi Hasegawa; Yasuhiro Asahina; Namiki Izumi; Hiroshi Yatsuhashi; Etsuro Orito; Takashi Joh; Masashi Mizokami
Journal:  J Clin Microbiol       Date:  2007-07-25       Impact factor: 5.948

Review 3.  Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Mariantonietta Pisaturo; Margherita Macera; Nicola Coppola
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

4.  An expert consensus for the management of chronic hepatitis B in Asian Americans.

Authors:  M J Tong; C Q Pan; S-H B Han; D S-K Lu; S Raman; K-Q Hu; J K Lim; H W Hann; A D Min
Journal:  Aliment Pharmacol Ther       Date:  2018-02-26       Impact factor: 8.171

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.